1.Clinical practice guidelines for the management of biliary tract cancers 2019: the 3rd English edition
Masato NAGINO ; Satoshi HIRANO ; Hideyuki YOSHITOMI ; Taku AOKI ; Katsuhiko UESAKA ; Michiaki UNNO ; Tomoki EBATA ; Masaru KONISHI ; Keiji SANO ; Kazuaki SHIMADA ; Hiroaki SHIMIZU ; Ryota HIGUCHI ; Toshifumi WAKAI ; Hiroyuki ISAYAMA ; Takuji OKUSAKA ; Toshio TSUYUGUCHI ; Yoshiki HIROOKA ; Junji FURUSE ; Hiroyuki MAGUCHI ; Kojiro SUZUKI ; Hideya YAMAZAKI ; Hiroshi KIJIMA ; Akio YANAGISAWA ; Masahiro YOSHIDA ; Yukihiro YOKOYAMA ; Takashi MIZUNO ; Itaru ENDO
Chinese Journal of Digestive Surgery 2021;20(4):359-375
The Japanese Society of Hepato-Biliary-Pancreatic Surgery launched the clinical practice guidelines for the management of biliary tract cancers (cholangiocarcinoma, gallbladder cancer, and ampullary cancer) in 2007, then published the 2nd version in 2014. In this 3rd version, clinical questions (CQs) were proposed on six topics. The recommendation, grade for recommendation, and statement for each CQ were discussed and finalized by an evidence-based approach. Recommendations were graded as grade 1 (strong) or grade 2 (weak) according to the concepts of the grading of recommendations assessment, development, and evaluation system. The 31 CQs covered the six topics: (1) prophylactic treatment, (2) diagnosis, (3) biliary drainage, (4) surgical treatment, (5) chemotherapy, and (6) radiation therapy. In the 31 CQs, 14 recommendations were rated strong and 14 recommendations weak. The remaining three CQs had no recommendation. Each CQ includes a statement of how the recommendations were graded. This latest guideline provides recommendations for important clinical aspects based on evidence. Future collaboration with the cancer registry will be key for assessing the guidelines and establishing new evidence.
2.Identification of LEF1 as a Susceptibility Locus for Kawasaki Disease in Patients Younger than 6 Months of Age.
Hea Ji KIM ; Sin Weon YUN ; Jeong Jin YU ; Kyung Lim YOON ; Kyung Yil LEE ; Hong Ryang KIL ; Gi Beom KIM ; Myung Ki HAN ; Min Seob SONG ; Hyoung Doo LEE ; Kee Soo HA ; Sejung SOHN ; Ryota EBATA ; Hiromichi HAMADA ; Hiroyuki SUZUKI ; Yoichiro KAMATANI ; Michiaki KUBO ; Kaoru ITO ; Yoshihiro ONOUCHI ; Young Mi HONG ; Gi Young JANG ; Jong Keuk LEE
Genomics & Informatics 2018;16(2):36-41
Kawasaki disease (KD) is an acute febrile vasculitis predominately affecting infants and children. The dominant incidence age of KD is from 6 months to 5 years of age, and the incidence is unusual in those younger than 6 months and older than 5 years of age. We tried to identify genetic variants specifically associated with KD in patients younger than 6 months or older than 5 years of age. We performed an age-stratified genome-wide association study using the Illumina HumanOmni1-Quad BeadChip data (296 cases vs. 1,000 controls) and a replication study (1,360 cases vs. 3,553 controls) in the Korean population. Among 26 candidate single nucleotide polymorphisms (SNPs) tested in replication study, only a rare nonsynonymous SNP (rs4365796: c.1106C>T, p.Thr369Met) in the lymphoid enhancer binding factor 1 (LEF1) gene was very significantly associated with KD in patients younger than 6 months of age (odds ratio [OR], 3.07; p(combined) = 1.10 × 10⁻⁵), whereas no association of the same SNP was observed in any other age group of KD patients. The same SNP (rs4365796) in the LEF1 gene showed the same direction of risk effect in Japanese KD patients younger than 6 months of age, although the effect was not statistically significant (OR, 1.42; p = 0.397). This result indicates that the LEF1 gene may play an important role as a susceptibility gene specifically affecting KD patients younger than 6 months of age.
Asian Continental Ancestry Group
;
Child
;
Genome-Wide Association Study
;
Humans
;
Incidence
;
Infant
;
Lymphoid Enhancer-Binding Factor 1
;
Mucocutaneous Lymph Node Syndrome*
;
Polymorphism, Single Nucleotide
;
Vasculitis